DGAT2 and ACC Inhibitor Combination for NAFLD/NASH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic fatty liver disease (NAFLD) and related conditions, such as nonalcoholic steatohepatitis (NASH), are limited, and there is a need for effective pharmacological interventions to address hepatic steatosis, inflammation, and fibrosis.
Innovation Solution
A combination therapy using (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide as a DGAT2 inhibitor and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid as an ACC inhibitor is administered to reduce hepatic steatosis, inflammation, and fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with DGAT2 inhibitor and ACC inhibitor is used, then therapeutic efficacy for NAFLD/NASH is improved, but treatment complexity increases
Solution Approach 1:
The patent combines two separate pharmacological mechanisms (DGAT2 inhibition and ACC inhibition) into a single combination therapy regimen. This merging of multiple therapeutic agents targets different pathways in NAFLD/NASH pathogenesis simultaneously, achieving synergistic therapeutic effects while managing the complexity through coordinated dosing and administration protocols
2Quantity of substance
If ACC inhibition is used to reduce hepatic steatosis, then liver fat content is reduced, but treatment options remain limited
Solution Approach 1:
The combination therapy regimen is designed to address multiple aspects of NAFLD/NASH simultaneously: reducing hepatic steatosis through DGAT2 inhibition, decreasing inflammation through ACC inhibition, and improving insulin sensitivity. This multi-functional approach expands treatment versatility beyond single-target therapies, making the treatment regime adaptable to various disease manifestations
Data Source
AI summary
A method for treating fatty liver disease and related diseases or disorders with a therapeutically effective amount of a composition comprising from about 25 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.